Free tool
FAERS Monitor: Vimizim
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125460 or its brand name (Vimizim, Elosulfase Alfa). Reports on generic versions are filed under their own applications.
Reports
5,517
Serious
2,246
41% of reports
Hospitalization
1,167
Death reported
134
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pyrexia742
- cough353
- vomiting333
- malaise287
- headache261
- pain241
- dyspnoea238
- nausea228
- fatigue202
- nasopharyngitis199
- pneumonia172
- oxygen saturation decreased155
- product dose omission155
- pain in extremity146
- arthralgia140
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2014 | 151 |
| 2015 | 436 |
| 2016 | 526 |
| 2017 | 445 |
| 2018 | 440 |
| 2019 | 470 |
| 2020 | 406 |
| 2021 | 475 |
| 2022 | 465 |
| 2023 | 467 |
| 2024 | 425 |
| 2025 | 460 |
| 2026 | 351 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,642 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| oxygen saturation decreasedSignal | 155 | 10.5 | 9.0 | 1,329 |
| product dose omissionSignal | 155 | 9.1 | 7.8 | 1,106 |
| pyrexiaSignal | 742 | 8.2 | 7.7 | 4,745 |
| coughSignal | 353 | 4.8 | 4.3 | 1,072 |
| nasopharyngitisSignal | 199 | 4.1 | 3.6 | 470 |
| vomitingSignal | 333 | 2.7 | 2.4 | 363 |
| malaiseSignal | 287 | 2.5 | 2.2 | 261 |
| pneumoniaSignal | 172 | 2.0 | 1.7 | 90 |
| pain in extremity | 146 | 1.9 | 1.6 | 61 |
| dyspnoea | 238 | 1.6 | 1.4 | 55 |
| headache | 261 | 1.6 | 1.4 | 58 |
| pain | 241 | 1.5 | 1.3 | 40 |
| arthralgia | 140 | 1.3 | 1.1 | 9 |
| nausea | 228 | 1.1 | 1.0 | 2 |
| fatigue | 202 | 1.0 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.